Accès gratuit
Editorial
Numéro
Med Sci (Paris)
Volume 31, Numéro 8-9, Août–Septembre 2015
Page(s) 707 - 708
Section Éditorial
DOI https://doi.org/10.1051/medsci/20153108001
Publié en ligne 4 septembre 2015
  1. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 1893 ; 105 : 487–511. [CrossRef]
  2. Ehrlich P. Über den jetzigen stand der karzinomforschung. Ned Tijdschr Geneeskd 1909 ; 5 : 273–290.
  3. Old LJ, Clark DA, Benacerraf B. Effect of bacillus Calmette Guérin infection on transplanted tumors in the mouse. Nature 1959 ; 184 : 291–292. [CrossRef] [PubMed]
  4. Mathé G, Bernard J, Schwarzenberg L, et al. Trial treatment of patients afflicted with acute leukemia in remission with total irradiation followed by homologous bone marrow transfusion. Rev Fr Etud Clin Biol 1959 ; 4 : 675–704. [PubMed]
  5. Burnet MF. Cancer: a biological approach. I. The processes of control. Br Med J 1957 ; 780 : 779–786. [CrossRef]
  6. Thomas L. Delayed hypersensitivity in health and disease. In : Lawrence HS, ed. Cellular and humoral aspects of the hypersensitive states. New York : Hoeber-Harper, 1959 : 529–533.
  7. Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature 1975 ; 256 : 495–497. [CrossRef] [PubMed]
  8. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006 ; 313 : 1960–1964. [CrossRef] [PubMed]
  9. Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008 ; 26 : 4410–4417. [CrossRef] [PubMed]
  10. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012 ; 12 : 298–306. [CrossRef] [PubMed]
  11. Topalian S, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015 ; 27 : 450–461. [CrossRef] [PubMed]
  12. McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 2015 ; 33 : 2013–2020. [CrossRef] [PubMed]
  13. Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015 ; 33 : 2004–2012. [CrossRef] [PubMed]
  14. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015 ; 372 : 2006–2017. [CrossRef] [PubMed]
  15. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015 ; 372 : 2521–2532. [CrossRef] [PubMed]
  16. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008 ; 321 : 974–977. [CrossRef] [PubMed]
  17. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cells therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014 ; 6 : 224ra25. [CrossRef]
  18. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumor-specific mutant antigens. Nature 2014 ; 515 : 577–581. [CrossRef] [PubMed]
  19. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015 ; 348 : 69–74. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.